Lansen Pharmaceutical Holdings Dividenden en inkoop

Dividend criteriumcontroles 1/6

Lansen Pharmaceutical Holdings is een dividendbetalend bedrijf met een huidig rendement van 2.7% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

2.7%

Dividendrendement

2.9%

Terugkoop Rendement

Totaal aandeelhoudersrendement	5.6%
Toekomstig dividendrendement	n/a
Dividendgroei	-13.4%
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	36%

Recente updates van dividend en inkoop

Recent updates

We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings

Dec 28

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: De dividendbetalingen van 503 zijn de afgelopen 10 jaar volatiel geweest.

Groeiend dividend: De dividendbetalingen van 503 zijn de afgelopen 10 jaar gedaald.

Dividendrendement versus markt

Lansen Pharmaceutical Holdings Dividendrendement versus markt

Hoe verhoudt 503 dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (503)	2.7%
Markt onderkant 25% (HK)	3.3%
Markt Top 25% (HK)	8.1%
Gemiddelde industrie (Pharmaceuticals)	3.8%
Analist prognose (503) (tot 3 jaar)	n/a

Opmerkelijk dividend: Het dividend van 503 ( 2.7% ) is niet noemenswaardig vergeleken met de onderste 25% van de dividendbetalers op de Hong Kong markt ( 3.3% ).

Hoog dividend: Het dividend 503 ( 2.7% ) is laag vergeleken met de top 25% van dividendbetalers in de Hong Kong markt ( 8.06% ).

Winstuitkering aan aandeelhouders

Verdiendekking: Met zijn redelijk lage payout ratio ( 35.7% ) worden de dividendbetalingen van 503 ruimschoots gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Gezien de hoge cash payout ratio ( 305.5% ) worden de dividendbetalingen van 503 niet goed gedekt door de kasstromen.

Lansen Pharmaceutical Holdings Dividenden en inkoop

Dividend criteriumcontroles 1/6

Belangrijke informatie

Recente updates van dividend en inkoop

Lansen Pharmaceutical Holdings Limited Declares a Special Dividend, Payable on 28 September 2021

Recent updates

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

Lansen Pharmaceutical Updates Withdrawal of Listing of Shares on Stock Exchange

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 27%

Investor sentiment improves as stock rises 20%

Does Lansen Pharmaceutical Holdings (HKG:503) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$0.013 (vs US$0.017 in 1H 2022)

New major risk - Revenue and earnings growth

Lansen Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 24, 2023

Investor sentiment improves as stock rises 18%

Is Lansen Pharmaceutical Holdings (HKG:503) Using Too Much Debt?

Full year 2022 earnings released

Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Twelve Months Ended 31 December 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Lansen Pharmaceutical Holdings (HKG:503) Has A Rock Solid Balance Sheet

Lansen Pharmaceutical Holdings Limited Appoints Zhu Xun as Independent Non-Executive Director and Member of the Remuneration Committee

First half 2022 earnings released: EPS: US$0.017 (vs US$0.004 in 1H 2021)

Lansen Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Lansen Pharmaceutical Holdings Limited Approves to Elect Chan Ching Har, Eliza as an Independent Non-Executive Director

Investor sentiment improved over the past week

Lansen Pharmaceutical Holdings Limited has completed a Follow-on Equity Offering in the amount of SGD 59.424 million.

Full year 2021 earnings released: EPS: US$0.002 (vs US$0.22 in FY 2020)

Lansen Pharmaceutical Holdings Limited, Annual General Meeting, Jun 23, 2022

Lansen Pharmaceutical Holdings Limited Announces Resignation of Stephen Burnau Hunt as Non-Executive Director and Member of the Remuneration Committee

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Lansen Pharmaceutical Holdings Limited to Report Fiscal Year 2021 Results on Feb 28, 2022

Lansen Pharmaceutical Holdings Limited Announces Executive Changes

Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Year Ended December 31, 2021

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

First half 2021 earnings released: EPS US$0.004 (vs US$0.24 in 1H 2020)

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Lansen Pharmaceutical Holdings Limited Declares a Special Dividend, Payable on 28 September 2021

Investor sentiment improved over the past week

Chairman recently bought HK$313k worth of stock

Full year 2020 earnings released: EPS US$0.22 (vs US$0.045 in FY 2019)

Lansen Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day high: HK$1.92

We're Not So Sure You Should Rely on Lansen Pharmaceutical Holdings's (HKG:503) Statutory Earnings

Chairman recently bought HK$1.4m worth of stock

New 90-day high: HK$0.87

New 90-day high - HK$0.81

Lansen Pharmaceutical Holdings Limited to Report First Half, 2020 Results on Aug 27, 2020

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend